<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский вестник детской хирургии, анестезиологии и реаниматологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2219-4061</issn><issn publication-format="electronic">2587-6554</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1885</article-id><article-id pub-id-type="doi">10.17816/psaic1885</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Case reports</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Клинические случаи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Pathogenetic phenotypes of bone cement implantation syndrome in pediatric oncology patients: Case reports</article-title><trans-title-group xml:lang="ru"><trans-title>Патогенетические фенотипы синдрома имплантации костного цемента у детей с онкологическими заболеваниями: клинические наблюдения</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>儿童肿瘤患者骨水泥植入综合征的病理生理表型及临床观察</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4364-8937</contrib-id><contrib-id contrib-id-type="spin">2128-9110</contrib-id><name-alternatives><name xml:lang="en"><surname>Leonov</surname><given-names>Nikolai P.</given-names></name><name xml:lang="ru"><surname>Леонов</surname><given-names>Николай Петрович</given-names></name><name xml:lang="zh"><surname>Leonov</surname><given-names>Nikolai P.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><bio xml:lang="zh"><p>MD, Cand. Sci. (Medicine)</p></bio><email>NikoLeonov@ya.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-7200-8278</contrib-id><name-alternatives><name xml:lang="en"><surname>Leonova</surname><given-names>Viktoria A.</given-names></name><name xml:lang="ru"><surname>Леонова</surname><given-names>Виктория Алексеевна</given-names></name><name xml:lang="zh"><surname>Leonova</surname><given-names>Viktoria A.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>NikoLeonov@ya.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7945-2565</contrib-id><contrib-id contrib-id-type="spin">4572-8611</contrib-id><name-alternatives><name xml:lang="en"><surname>Schukin</surname><given-names>Vladislav V.</given-names></name><name xml:lang="ru"><surname>Щукин</surname><given-names>Владислав Владимирович</given-names></name><name xml:lang="zh"><surname>Schukin</surname><given-names>Vladislav V.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><bio xml:lang="zh"><p>MD, Cand. Sci. (Medicine)</p></bio><email>schukin.vv@ya.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8129-0545</contrib-id><name-alternatives><name xml:lang="en"><surname>Shcherbakov</surname><given-names>Alexey P.</given-names></name><name xml:lang="ru"><surname>Щербаков</surname><given-names>Алексей Петрович</given-names></name><name xml:lang="zh"><surname>Shcherbakov</surname><given-names>Alexey P.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alexey.shcherbakov@dgoi.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1093-8938</contrib-id><contrib-id contrib-id-type="spin">9457-4580</contrib-id><name-alternatives><name xml:lang="en"><surname>Madonov</surname><given-names>Pavel G.</given-names></name><name xml:lang="ru"><surname>Мадонов</surname><given-names>Павел Геннадьевич</given-names></name><name xml:lang="zh"><surname>Madonov</surname><given-names>Pavel G.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>профессор, д-р мед. наук</p></bio><bio xml:lang="zh"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><email>pmadonov@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8417-3555</contrib-id><contrib-id contrib-id-type="spin">4414-0677</contrib-id><name-alternatives><name xml:lang="en"><surname>Lazarev</surname><given-names>Vladimir V.</given-names></name><name xml:lang="ru"><surname>Лазарев</surname><given-names>Владимир Викторович</given-names></name><name xml:lang="zh"><surname>Lazarev</surname><given-names>Vladimir V.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><bio xml:lang="zh"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><email>lazarev_vv@inbox.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5230-5725</contrib-id><contrib-id contrib-id-type="spin">1729-8002</contrib-id><name-alternatives><name xml:lang="en"><surname>Spiridonova</surname><given-names>Elena A.</given-names></name><name xml:lang="ru"><surname>Спиридонова</surname><given-names>Елена Александровна</given-names></name><name xml:lang="zh"><surname>Spiridonova</surname><given-names>Elena A.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><bio xml:lang="zh"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><email>spiridonova.e.a@gmail.com</email><xref ref-type="aff" rid="aff4"/><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4451-3233</contrib-id><contrib-id contrib-id-type="spin">2836-2349</contrib-id><name-alternatives><name xml:lang="en"><surname>Grachev</surname><given-names>Nikolai S.</given-names></name><name xml:lang="ru"><surname>Грачев</surname><given-names>Николай Сергеевич</given-names></name><name xml:lang="zh"><surname>Grachev</surname><given-names>Nikolai S.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><bio xml:lang="zh"><p>MD, Dr. Sci. (Medicine)</p></bio><email>nick-grachev@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology</institution></aff><aff><institution xml:lang="ru">Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева</institution></aff><aff><institution xml:lang="zh">Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Novosibirsk State Medical University</institution></aff><aff><institution xml:lang="ru">Новосибирский государственный медицинский университет</institution></aff><aff><institution xml:lang="zh">Novosibirsk State Medical University</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Pirogov Russian National Research Medical University</institution></aff><aff><institution xml:lang="ru">Российский национальный исследовательский медицинский университет им. Н.И. Пирогова</institution></aff><aff><institution xml:lang="zh">Pirogov Russian National Research Medical University</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Russian University of Medicine</institution></aff><aff><institution xml:lang="ru">Российский университет медицины</institution></aff><aff><institution xml:lang="zh">Russian University of Medicine</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology</institution></aff><aff><institution xml:lang="ru">Федеральный научно-клинический центр реаниматологии и реабилитологии</institution></aff><aff><institution xml:lang="zh">Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-04-23" publication-format="electronic"><day>23</day><month>04</month><year>2025</year></pub-date><volume>15</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><issue-title xml:lang="zh"/><fpage>91</fpage><lpage>100</lpage><history><date date-type="received" iso-8601-date="2025-01-10"><day>10</day><month>01</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-02-11"><day>11</day><month>02</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Эко-Вектор</copyright-statement><copyright-statement xml:lang="zh">Copyright ©; 2025,</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://rps-journal.ru/jour/article/view/1885">https://rps-journal.ru/jour/article/view/1885</self-uri><abstract xml:lang="en"><p>Bone cement implantation syndrome in pediatric oncology patients remains poorly understood. A multimodal pathogenetic model determines the existence of two distinct clinical and pathophysiological phenotypes of this condition: the anaphylactic phenotype (distributive shock) and the embolic phenotype (obstructive shock). Both phenotypes are associated with coagulopathy, with thrombotic catastrophes representing their most severe manifestation. The pathways of thrombotic complications depend on the clinical and pathophysiological phenotype of this critical condition: in anaphylactic bone cement implantation syndrome, they are primarily driven by microthrombogenesis, whereas in embolic bone cement implantation syndrome, both microthrombogenesis and fibrinogenesis contribute to thrombosis. In the first clinical case, bone cement implantation syndrome developed through an anaphylactic mechanism. A boy with femoral osteosarcoma underwent bone cement spacer implantation following tumor resection. We assume that sensitization occurred during this period. This is supported by the presence of a periosteal reaction in the upper third of the right femur, as revealed by computed tomography (CT). During knee endoprosthesis implantation, the patient developed severe hemodynamic instability, cardiac rhythm disturbances, and oxygenation impairment. Despite the characteristic microthrombogenesis mechanism of this pathophysiological phenotype, multiorgan failure and life-threatening thrombotic complications were successfully averted due to effective anti-shock measures and early initiation of heparin therapy. Second clinical case illustrates the embolic phenotype of bone cement implantation syndrome. A boy with tibial osteosarcoma experienced hypotension, tachyarrhythmia, desaturation, and hypocapnia following bone cement application during endoprosthetic surgery. Postoperatively, desaturation persisted. CT revealed a mural defect in the left pulmonary artery and segmental obstructions in multiple branches of both lungs, along with elevated D-dimer levels and echocardiographic evidence of increased right heart pressure. By postoperative day 20, oxygen saturation normalized (the patient was breathing ambient air). CT imaging showed resolution of the filling defect in the left pulmonary artery; however, signs of segmental pulmonary artery obstruction remained in the upper and middle lobes of the right lung and the lower lobe of the left lung. Thus, the hemodynamic catastrophe in the embolic phenotype of bone cement implantation syndrome represents a classic presentation of obstructive shock with subsequent thrombotic complications, driven by the combined mechanisms of microthrombogenesis and fibrinogenesis. The proposed pathogenetic phenotyping of bone cement implantation syndrome allows for a targeted approach to the prevention and treatment of hemodynamic and thrombotic complications in affected patients. This approach appears to be relevant and has the potential to reduce the incidence of adverse outcomes and complications.</p></abstract><trans-abstract xml:lang="ru"><p>Синдром имплантации костного цемента у детей с онкологической патологией изучен недостаточно хорошо. Мультимодальная модель патогенеза детерминирует существование двух клинико-патофизиологических фенотипов данного состояния: анафилактического (дистрибутивный шок) и эмболического (обструктивный шок). Оба фенотипа связаны с развитием коагулопатии, крайним выражением которой является реализация тромботических катастроф. Пути реализации тромботических осложнений зависят от клинико-патофизиологического фенотипа данного критического состояния: при анафилактическом фенотипе они связаны с процессом микротромбогенеза, а при эмболическом как с микротромбогенезом, так и фибриногенезом. В первом клиническом случае представлено развитие синдрома имплантации костного цемента через механизм анафилаксии. У мальчика был установлен цементный спейсер после первичного удаления остеосаркомы бедренной кости. Мы предполагаем, что в этот период времени произошла сенсебилизация. Этот факт подтверждается наличием признаков реакции надкостницы в верхней трети правой бедренной кости по данным компьютерной томографии. Во время применения костного цемента при эндопротезировании коленного сустава возникли выраженные расстройства гемодинамики, сердечного ритма и оксигенации. Несмотря на характерный для данного патофизиологического фенотипа механизм микротромбогенеза, выраженной полиорганной недостаточности и реализации жизнеугрожающих тромботических осложнений удалось избежать благодаря эффективно проведенным противошоковым мероприятиям и раннему началу гепаринотерапии. Второй клинический случай иллюстрирует эмболический фенотип синдрома имплантации костного цемента. У мальчика с остеогенной саркомой большеберцовой кости при применении костного цемента во время эндопротезирования возник эпизод гипотензии, тахиаритмии, десатурации и гипокапнии. После операции сохраняется десатурация и по данным компьютерной томографии выявлены пристеночный дефект левой ветви легочной артерии и признаки обструкции сегментарных ветвей легочных артерий обоих легких, высокий уровень D-димера, эхопризнаки увеличения давления в правых отделах сердца. На 20-е сутки после операции отмечается нормализация сатурации при дыхании воздухом. По данным компьютерной томографии дефект заполнения левой легочной артерии отсутствует, но сохраняются признаки обструкции ветвей легочной артерии в верхней и средней доле справа, в нижней доле левого легкого. Таким образом, гемодинамическая катастрофа эмболического фенотипа синдрома имплантации костного цемента представляет собой классическую картину обструктивного шока с последующим развитием тромботических осложнений, благодаря объединению механизмов микротромбогенеза и фибриногенеза. Предложенное нами патогенетическое фенотипирование синдрома имплантации костного цемента позволяет разработать цель-ориентированную стратегию профилактики и лечения гемодинамических и тромботических проявлений этого состояния. Данный подход представляется актуальным и способным снизить частоту неблагоприятных исходов и осложнений.</p></trans-abstract><trans-abstract xml:lang="zh"><p>儿童肿瘤患者的骨水泥植入综合征（bone cement implantation syndrome, BCIS）目前尚未得到充分研究。其多模式发病机制可分为两种临床病理生理表型：过敏反应型（分布性休克）和栓塞型（阻塞性休克）。两种表型均与凝血病相关，其最严重的表现形式为血栓危象。血栓形成的具体机制取决于该综合征的病理生理表型：过敏性表型主要涉及微血栓形成；栓塞性表型既涉及微血栓形成，也涉及纤维蛋白形成。病例 1（过敏性表型）：本病例展示了骨水泥植入综合征通过过敏机制发展的过程。一名男孩因股骨骨肉瘤接受原发性肿瘤切除术后植入骨水泥间隔器（cement spacer）。我们推测，在此阶段可能发生了致敏反应。这一推测得到了计算机断层扫描（CT）结果的支持，具体表现为右股骨上段骨膜反应的存在。在膝关节置换术中应用骨水泥后，患儿出现严重的血流动力学紊乱、心律失常和氧合障碍。尽管该表型的典型机制为微血栓形成，但得益于有效的抗休克治疗和早期肝素抗凝治疗，成功避免了严重的多器官功能衰竭和危及生命的血栓形成并发症。病例 2（栓塞性表型）：本病例展示了骨水泥植入综合征的栓塞性表型。另一名男孩因胫骨成骨肉瘤接受膝关节置换术，在术中骨水泥植入后，出现低血压、心动过速性心律失常、低氧血症和低碳酸血症。术后患儿持续出现低氧血症，CT检查显示左肺动脉分支壁缺损，并存在双肺段动脉分支阻塞；D-二聚体水平升高，超声心动图提示右心腔压力增高。术后第20天，患儿吸空气时血氧饱和度恢复正常。CT检查显示左肺动脉的填充缺损消失，但右肺上叶、中叶及左肺下叶的肺动脉分支仍存在阻塞。该病例表明，栓塞性BCIS的血流动力学危象表现为典型的阻塞性休克，并且微血栓形成与纤维蛋白生成的协同作用导致了血栓并发症的发生。本研究提出的BCIS病理生理表型分类有助于制定针对性预防和 治疗策略，以优化血流动力学管理并降低血栓相关并发症的发生率。该方法具有重要临床价值， 并可能降低不良结局及并发症的发生率。</p></trans-abstract><kwd-group xml:lang="en"><kwd>bone cement implantation syndrome</kwd><kwd>thrombosis pathogenesis phenotypes</kwd><kwd>children</kwd><kwd>intensive therapy</kwd><kwd>oncology</kwd><kwd>case reports</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>синдром имплантации костного цемента</kwd><kwd>фенотипы патогенеза тромбоза</kwd><kwd>дети</kwd><kwd>интенсивная терапия</kwd><kwd>онкологические заболевания</kwd><kwd>клинические наблюдения</kwd></kwd-group><kwd-group xml:lang="zh"><kwd>骨水泥植入综合征</kwd><kwd>血栓形成机制表型</kwd><kwd>儿童</kwd><kwd>重症监护</kwd><kwd>肿瘤疾病</kwd><kwd>临床观察</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Vaishya R, Chauhan M, Vaish A. Bone cement. J Clin Orthop Trauma. 2013;4(4):157–163. doi: 10.1016/j.jcot.2013.11.005</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Bonfait H, Delaunay C, De Thomasson E, et al. Bone cement implantation syndrome in hip arthroplasty: Frequency, severity and prevention. Orthop Traumatol Surg Res. 2022;108(2):103139. doi: 10.1016/j.otsr.2021.103139 EDN: VLXUNG</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Al-Husinat L, Jouryyeh B, Al Sharie S, et al. Bone cement and its anesthetic complications: a narrative review. J Clin Med. 2023;12(6):2105. doi: 10.3390/jcm12062105 EDN: FYOEKP</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Schwarzkopf E, Sachdev R, Flynn J, et al. Occurrence, risk factors, and outcomes of bone cement implantation syndrome after hemi and total hip arthroplasty in cancer patients. J Surg Oncol. 2019;120(6):1008–1015. doi: 10.1002/jso.25675</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Yang TH, Yang RS, Lin CP, et al. Bone cement implantation syndrome in bone tumor surgeries: incidence, risk factors, and clinical experience. Orthop Surg. 2021;13(1):109–115. doi: 10.1111/os.12842 EDN: WFRYVE</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Donaldson AJ, Thomson HE, Harper NJ, et al. Bone cement implantation syndrome. Br J Anaesth. 2009;102(1):12–22. doi: 10.1093/bja/aen328</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Kalra A, Sharma A, Palaniswamy C, et al. Diagnosis and management of bone cement implantation syndrome: case report and brief review. Am J Ther. 2013;20(1):121–125. doi: 10.1097/MJT.0b013e31820b3de3</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Segerstad MHA. The bone cement implantation syndrome — epidemiology, pathophysiology and prevention [Doctoral thesis]. University of Gothenburg: Sweden; 2019. Available from: https://gupea.ub.gu.se/handle/2077/60777</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Chang JC. Disseminated intravascular coagulation: new identity as endotheliopathy-associated vascular microthrombotic disease based on in vivo hemostasis and endothelial molecular pathogenesis. Thrombosis J. 2020;18(1):1–21. doi: 10.1186/s12959-020-00231-0 EDN: KLNHDV</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Dahl OE, Pripp AH, Jaradeh M, et al. The bone cement hypercoagulation syndrome: pathophysiology, mortality, and prevention. Clin Appl Thromb Hemost. 2023;29. doi: 10.1177/10760296231198036 EDN: VYMNRA</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. J Allergy Clin Immunol. 2017;140(2):335–348. doi: 10.1016/j.jaci.2017.06.003</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Abbas M, Moussa M, Akel H. Type I hypersensitivity reaction. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>García-Mansilla A, Castro Lalín A, Holc F, et al. Intraoperative unfractionated heparin before femoral component cementation should be avoided in femoral neck fracture treated with hybrid total hip arthroplasty. Eur J Orthop Surg Traumatol. 2023;33(6):2547–2554. doi: 10.1007/s00590-023-03472-7 EDN: UTWZVN</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Hitti WA, Wali RK, Weinman EJ, et al. Cholesterol embolization syndrome induced by thrombolytic therapy. Am J Cardiovasc Drugs. 2008;8(1):27–34. doi: 10.2165/00129784-200808010-00004 EDN: LLJGUK</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Berkun Y, Haviv YS, Schwartz LB, et al. Heparin-induced recurrent anaphylaxis. Clin Exp Allergy. 2004;34(12):1916–1918. doi: 10.1111/j.1365-2222.2004.02129.x</mixed-citation></ref></ref-list></back></article>
